動的共有結合化学生成研究に基づく効率的なペプチド合成技術

動的共有結合化学生成研究に基づく効率的なペプチド合成技術

Background and Challenges

Since the first peptide gly-gly was synthesized in 1901, peptide synthesis has undergone more than 100 years of development, and as an important participant in life activities, it has shown great potential in the fields of drug discovery and development, biomaterials, and cosmetics. Traditional peptide synthesis methods are inefficient, costly, and environmentally polluting, which seriously restrict their wide application. The development of efficient, green and economical peptide synthesis technology has become an urgent challenge. ここ, based on the theoretical foundation of scientific research, we apply the theory to practice and successfully realize the application of catalytic peptide synthesis technology in actual production.


Technological breakthrough

Bifunctional organic small molecule catalyst: Using thiourea-tertiary amine synergistic catalysis, we successfully avoided the involvement of metal and realized the green coupling technology without metal.

  • Unique reaction mechanism: tertiary amine pulls hydrogen to improve the nucleophilicity of amino group, and thiourea’s rigid structure realizes the function of capturing the amino group, thus realizing the fixed-point catalysis.
  • Significantly improved coupling efficiency: the coupling efficiency of a single step under liquid phase conditions has been shortened to 5 minutes, and the coupling efficiency is as high as 99%.
  • Green chemistry technology: water/ionic liquid system replaces DMF to reduce organic waste emission, and the by-product is only water, simple post-processing, and suitable for continuous flow reactor, realizing continuous peptide synthesis on the scale of kilograms.

結論

The thiourea-tertiary amine co-catalyzed peptide synthesis technology can rapidly construct peptide libraries for high-throughput screening, significantly shorten the R&D cycle of anticancer and antiviral drugs, support the large-scale production of complex peptides, and promote more peptide drugs to enter into the clinical research. It reduces the use of reagents and solvents, and successfully lowers the cost of peptide synthesis, and can rapidly realize the large-scale synthesis of peptides.

管理者のアバター

アレックス・チャン

ペプチド業界アナリスト & 国際サプライチェーンスペシャリスト ペプチド合成製造の専門研究者, 生化学原料貿易, および世界的な医薬品サプライチェーン. GMPグレードの治療用ペプチドを専門としています, 化粧品ペプチド, カスタムペプチド合成, および国境を越えた市場政策分析.

Alex Zhang は、世界的なペプチド合成技術を専門とする業界の専門アナリストです。, バイオ医薬品原料, および国際生化学貿易. ペプチド製造プロセスにおける豊富な経験, 固相合成技術, 品質管理基準, そして世界市場の動向, 彼は信頼できる業界ニュースを提供することに専念しています, 市場動向分析, 世界的な製薬会社向けのサプライチェーンに関する洞察, 化粧品原料販売業者, 研究所研究機関, および生化学物質の購入者. 彼の主な報道内容には治療用ペプチドが含まれます, 化粧品用活性ペプチド, 研究グレードのペプチド, カスタムCDMO合成サービス, 業界ポリシーの最新情報, 輸出関税の変更, および世界のペプチドサプライヤーの開発動向.

事実確認済み & 編集ガイドライン
レビュー者: 対象分野の専門家
Share this article
検索 ワッツアップ サービス 製品